Literature DB >> 19041023

Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?

P Pepe1, F Fraggetta, A Galia, G Grasso, S Piccolo, F Aragona.   

Abstract

OBJECTIVES: To evaluate the role of quantitative histologic findings in predicting nonorgan-confined (non-OC) prostate cancer (PCa) in patients undergoing saturation prostate biopsy (SPBx).
METHODS: A total of 69 patients who had undergone SPBx underwent radical retropubic prostatectomy. Their prostate-specific antigen level was <10 ng/mL, and 49 and 20 patients had T1c and T2 PCa, respectively. The following biopsy variables from the quantitative histologic examination were evaluated as predictive of OC vs non-OC PCa: Gleason score (<or=6 vs >6), total percentage of PCa (<or=20% vs >20%), greatest percentage of PCa (<or=50% vs >50%), number of PCa-positive cores (<or=2 vs >2), presence of PCa-positive cores in both lateral margins (yes vs no), and PCa localization (unilateral vs bilateral). The results obtained from patients who had undergone SPBx were compared with those of 183 patients who had undergone 12-core prostate biopsy before radical retropubic prostatectomy.
RESULTS: Overall, 32 patients had non-OC PCa. Among the men with Stage T1c PCa, the quantitative histologic findings were predictive of non-OC PCa in 12 of 17 cases. The area under the receiver operating characteristic curve was 0.935 +/- 0.29, supporting the high accuracy of quantitative histologic examination in predicting for non-OC PCa. The sensitivity in patients who underwent SPBx vs the 12-core biopsy was 78.1% and 89.4%, respectively. Also, although the specificity of each histologic parameter was significantly lower in the SPBx group, it was equivalent using quantitative histologic examination (85.6% vs 86.5%).
CONCLUSIONS: In the preoperative staging of patients with clinical Stage T1c-T2 PCa and a prostate-specific antigen level <10 ng/mL who had undergone SPBx, quantitative histologic examination demonstrated good accuracy in predicting for non-OC PCa only when all pathological variables were considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041023     DOI: 10.1016/j.urology.2008.05.045

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

2.  Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models.

Authors:  Hailang Liu; Kun Tang; Ejun Peng; Liang Wang; Ding Xia; Zhiqiang Chen
Journal:  Cancer Manag Res       Date:  2020-12-22       Impact factor: 3.989

3.  Anterior prostate biopsy at initial and repeat evaluation: is it useful to detect significant prostate cancer?

Authors:  Pietro Pepe; Michele Pennisi; Filippo Fraggetta
Journal:  Int Braz J Urol       Date:  2015 Sep-Oct       Impact factor: 1.541

4.  Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study.

Authors:  Junlong Zhuang; Yansheng Kan; Yuwen Wang; Alessandro Marquis; Xuefeng Qiu; Marco Oderda; Haifeng Huang; Marco Gatti; Fan Zhang; Paolo Gontero; Linfeng Xu; Giorgio Calleris; Yao Fu; Bing Zhang; Giancarlo Marra; Hongqian Guo
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

5.  Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins.

Authors:  M Quentin; L Schimmöller; T Ullrich; B Valentin; D Demetrescu; R Al-Monajjed; D Mally; I Esposito; P Albers; G Antoch; C Arsov
Journal:  Abdom Radiol (NY)       Date:  2022-05-16

6.  Frozen section utilization to omit systematic biopsy in diagnosing high risk prostate cancer.

Authors:  Jong Hyun Tae; Hyun Jung Jin; Tae Il Noh; Ji Sung Shim; Seok Ho Kang; Jun Cheon; Jeong Gu Lee; Sung Gu Kang
Journal:  Sci Rep       Date:  2022-08-24       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.